Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527771 | 0.90 | GAA (0.58) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL23995243 | 0.81 | GAA (0.49) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL10439170 | 0.81 | GAA (0.49) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL19961833 | 0.81 | GAA (0.56) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL3576904 | 0.81 | GAA (0.56) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL25094432 | 0.81 | GAA (0.56) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL529416 | 0.81 | POLB (0.70) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL13545621 | 0.79 | GAA (0.69) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL2296725 | 0.78 | POLB (0.58) | GAAALDH1A1POLBSMN1; SMN2KMT2A | |
| SCHEMBL2296722 | 0.78 | POLB (0.58) | GAAALDH1A1POLBSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640688-A1 | AVERMECTIN DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| EP-4538268-A1 | PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR | Guangzhou Fermion Technology Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023236945-A1 | PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR | 广州费米子科技有限责任公司 | 2023-12-14 | — | — | WO | disclosed |
| CN-117186074-A | Pyridazine-3-carboxamide compounds as TYK2 inhibitors | 广州费米子科技有限责任公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2855438-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | Galleon Pharmaceuticals, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2013181217-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| EP-2646423-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | Galleon Pharmaceuticals, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012074999-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-1997041128-A1 | 3-PYRAZOLIOMETHYLCEPHEM COMPOUNDS AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-06 | — | — | WO | disclosed |
| EP-0517041-A1 | New Cephem Compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | GAA 342/4885ALDH1A1 1551/4885POLB 1596/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | GAA 563/4885ALDH1A1 1328/4885POLB 1156/4885 |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, MTNR1B, NDUFB5 | GAA 530/4885ALDH1A1 1618/4885POLB 940/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | GAA 672/4885ALDH1A1 1328/4885POLB 604/4885 |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, SMPD4, NDUFB5 | GAA 563/4885ALDH1A1 1328/4885POLB 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.